162 related articles for article (PubMed ID: 33968653)
1. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.
Kremer L; von Brandenstein M; Wittersheim M; Koeditz B; Paffenholz P; Hellmich M; Pfister D; Heidenreich A; Nestler T
Transl Androl Urol; 2021 Apr; 10(4):1647-1655. PubMed ID: 33968653
[TBL] [Abstract][Full Text] [Related]
2. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
4. Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.
Nestler T; Kremer L; von Brandenstein M; Wittersheim M; Paffenholz P; Wagener-Ryczek S; Quaas A; Hellmich M; Müller S; Pfister D; Odenthal M; Heidenreich A
Cancer; 2023 Feb; 129(4):634-642. PubMed ID: 36504384
[TBL] [Abstract][Full Text] [Related]
5. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
6. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in Testicular Germ Cell Tumors: The Teratoma Challenge.
Yodkhunnatham N; Pandit K; Puri D; Yuen KL; Bagrodia A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396829
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
9. Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.
Belge G; Hennig F; Dumlupinar C; Grobelny F; Junker K; Radtke A; Dieckmann KP
Oncotarget; 2020 Apr; 11(16):1462-1473. PubMed ID: 32363003
[No Abstract] [Full Text] [Related]
10. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
11. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
12. A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis.
Piao J; Lafin JT; Scarpini CG; Nuño MM; Syring I; Dieckmann KP; Belge G; Ellinger J; Amatruda JF; Bagrodia A; Coleman N; Krailo MD; Frazier AL; Murray MJ
Clin Genitourin Cancer; 2021 Dec; 19(6):469-479. PubMed ID: 34629299
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
14. Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection.
Lafin JT; Kenigsberg AP; Meng X; Abe D; Savelyeva A; Singla N; Woldu SL; Lotan Y; Mauck RJ; Lewis CM; Margulis V; Wong D; Jia L; Kapur P; Xu L; Speir RW; Chesnut GT; Frazier AL; Strand DW; Coleman N; Murray MJ; Amatruda JF; Bagrodia A
Eur Urol Open Sci; 2021 Apr; 26():83-87. PubMed ID: 33997822
[TBL] [Abstract][Full Text] [Related]
15. Micro-RNA-371a-3p in Germ Cell Testicular Tumors on Diagnosis: A Prospective Case-Control Study in Turkish Population.
Kılınç MT; Göger YE; Özkent MS; Kılıç Ö; Okur Altındaş B; Yıldırım MS; Karalezli G
Urol J; 2024 Jun; 21(4):242-249. PubMed ID: 38629199
[TBL] [Abstract][Full Text] [Related]
16. Refining the serum miR-371a-3p test for viable germ cell tumor detection.
Lafin JT; Scarpini CG; Amini A; Konneh B; Howard JM; Gerald T; Nuno M; Piao J; Savelyeva A; Wang Z; Gagan J; Jia L; Lewis CM; Murray S; Sawa YC; Margulis V; Woldu SL; Strand DW; Coleman N; Amatruda JF; Frazier AL; Murray MJ; Bagrodia A
Sci Rep; 2023 Jun; 13(1):10558. PubMed ID: 37386046
[TBL] [Abstract][Full Text] [Related]
17. Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.
Ye F; Feldman DR; Valentino A; So R; Bromberg M; Khan S; Funt SA; Sheinfeld J; Solit DB; Pessin MS; Peerschke EI
J Mol Diagn; 2022 Aug; 24(8):867-877. PubMed ID: 35934321
[TBL] [Abstract][Full Text] [Related]
18. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
[TBL] [Abstract][Full Text] [Related]
19. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer.
Li R; Duplisea JJ; Petros FG; González GMN; Tu SM; Karam JA; Huynh TT; Ward JF
Eur Urol Oncol; 2021 Aug; 4(4):651-658. PubMed ID: 31412007
[TBL] [Abstract][Full Text] [Related]
20. Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation.
Boellaard WPA; Gillis AJM; van Leenders GJLH; Stoop H; van Agthoven T; Dorssers LCJ; Dinkelman-Smit M; Boormans JL; Looijenga LHJ
Andrology; 2019 Jul; 7(4):463-468. PubMed ID: 30786164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
